Literature DB >> 28554959

Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease.

Amy W Amara1, Lama M Chahine2, Chelsea Caspell-Garcia3, Jeffrey D Long3, Christopher Coffey3, Birgit Högl4, Aleksandar Videnovic5, Alex Iranzo6, Geert Mayer7, Nancy Foldvary-Schaefer8, Ron Postuma9, Wolfgang Oertel10,11, Shirley Lasch12, Ken Marek12, Tanya Simuni13.   

Abstract

BACKGROUND: Excessive daytime sleepiness (EDS) is common and disabling in Parkinson's disease (PD). Predictors of EDS are unclear, and data on biological correlates of EDS in PD are limited. We investigated clinical, imaging and biological variables associated with longitudinal changes in sleepiness in early PD.
METHODS: The Parkinson's Progression Markers Initiative is a prospective cohort study evaluating progression markers in participants with PD who are unmedicated at baseline (n=423) and healthy controls (HC; n=196). EDS was measured with the Epworth Sleepiness Scale (ESS). Clinical, biological and imaging variables were assessed for associations with EDS for up to 3 years. A machine learning approach (random survival forests) was used to investigate baseline predictors of incident EDS.
RESULTS: ESS increased in PD from baseline to year 3 (mean±SD 5.8±3.5 to 7.55±4.6, p<0.0001), with no change in HC. Longitudinally, EDS in PD was associated with non-tremor dominant phenotype, autonomic dysfunction, depression, anxiety and probable behaviour disorder, but not cognitive dysfunction or motor severity. Dopaminergic therapy was associated with EDS at years 2 and 3, as dose increased. EDS was also associated with presynaptic dopaminergic dysfunction, whereas biofluid markers at year 1 showed no significant associations with EDS. A predictive index for EDS was generated, which included seven baseline characteristics, including non-motor symptoms and cerebrospinal fluid phosphorylated-tau/total-tau ratio.
CONCLUSIONS: In early PD, EDS increases significantly over time and is associated with several clinical variables. The influence of dopaminergic therapy on EDS is dose dependent. Further longitudinal analyses will better characterise associations with imaging and biomarkers. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Biomarkers; Excessive daytime sleepiness; Non-motor symptoms; Parkinson’s disease; Sleep

Mesh:

Substances:

Year:  2017        PMID: 28554959      PMCID: PMC7282477          DOI: 10.1136/jnnp-2016-315023

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  46 in total

1.  Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Authors:  Richard K Bogan; Thomas Roth; Jonathan Schwartz; Maja Miloslavsky
Journal:  J Clin Sleep Med       Date:  2015-04-15       Impact factor: 4.062

Review 2.  Scales to assess sleep impairment in Parkinson's disease: critique and recommendations.

Authors:  Birgit Högl; Isabelle Arnulf; Cynthia Comella; Joaquim Ferreira; Alex Iranzo; Barbara Tilley; Claudia Trenkwalder; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Anette Schrag; Christopher G Goetz
Journal:  Mov Disord       Date:  2010-12-15       Impact factor: 10.338

3.  Sleepiness in Idiopathic REM Sleep Behavior Disorder and Parkinson Disease.

Authors:  Isabelle Arnulf; Dulce Neutel; Bastien Herlin; Jean-Louis Golmard; Smaranda Leu-Semenescu; Valérie Cochen de Cock; Marie Vidailhet
Journal:  Sleep       Date:  2015-10-01       Impact factor: 5.849

Review 4.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Authors:  Claire L Tomlinson; Rebecca Stowe; Smitaa Patel; Caroline Rick; Richard Gray; Carl E Clarke
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

5.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

6.  Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants.

Authors:  R Poryazova; D Benninger; D Waldvogel; C L Bassetti
Journal:  Eur Neurol       Date:  2010-01-16       Impact factor: 1.710

Review 7.  Excessive daytime sleepiness and unintended sleep in Parkinson's disease.

Authors:  David B Rye
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

Review 8.  Cholinergic dysfunction in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Neurol Neurosci Rep       Date:  2013-09       Impact factor: 5.081

9.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Authors:  Ju-Hee Kang; David J Irwin; Alice S Chen-Plotkin; Andrew Siderowf; Chelsea Caspell; Christopher S Coffey; Teresa Waligórska; Peggy Taylor; Sarah Pan; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Tanya Simuni; Caroline M Tanner; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; Brit Mollenhauer; John Q Trojanowski; Leslie M Shaw
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

10.  Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.

Authors:  Tanya Simuni; Jeffrey D Long; Chelsea Caspell-Garcia; Christopher S Coffey; Shirley Lasch; Caroline M Tanner; Danna Jennings; Karl D Kieburtz; Kenneth Marek
Journal:  Ann Clin Transl Neurol       Date:  2016-05-17       Impact factor: 4.511

View more
  24 in total

1.  Do Parkinson disease subject and caregiver-reported Epworth sleepiness scale reponses correlate?

Authors:  David R Shprecher; Charles H Adler; Nan Zhang; Holly A Shill; Christine M Belden; Erika Driver-Dunckley; Shyamal H Mehta; Kathryn J Davis; Lucia I Sue; Edward Zamrini; Thomas G Beach
Journal:  Clin Neurol Neurosurg       Date:  2020-02-06       Impact factor: 1.876

Review 2.  Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease.

Authors:  Priti Gros; Aleksandar Videnovic
Journal:  Clin Geriatr Med       Date:  2019-09-06       Impact factor: 3.076

Review 3.  The Relationship Between Anxiety Disorders and Parkinson's Disease: Clinical and Therapeutic Issues.

Authors:  Sandra Abou Kassm; Wadih Naja; Ramzi Haddad; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2021-03-03       Impact factor: 5.285

Review 4.  Longitudinal Studies of Sleep Disturbances in Parkinson's Disease.

Authors:  Zheyu Xu; Kirstie N Anderson; Nicola Pavese
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-26       Impact factor: 6.030

5.  The path linking excessive daytime sleepiness and activity of daily living in Parkinson's disease: the longitudinal mediation effect of autonomic dysfunction.

Authors:  Ying Huang; Sidan Du; Durong Chen; Yao Qin; Jing Cui; Hongjuan Han; Xiaoyan Ge; Wenlin Bai; Xinnan Zhang; Hongmei Yu
Journal:  Neurol Sci       Date:  2022-04-30       Impact factor: 3.830

Review 6.  Sleep Issues in Parkinson's Disease and Their Management.

Authors:  José Rafael P Zuzuárregui; Emmanuel H During
Journal:  Neurotherapeutics       Date:  2020-10-07       Impact factor: 7.620

Review 7.  Excessive Daytime Sleepiness in Parkinson's Disease: Clinical Implications and Management.

Authors:  Yun Shen; Jun-Ying Huang; Jie Li; Chun-Feng Liu
Journal:  Chin Med J (Engl)       Date:  2018-04-20       Impact factor: 2.628

8.  Clinical Predictors of Excessive Daytime Sleepiness in Patients with Parkinson's Disease.

Authors:  Bruno Terra Junho; Arthur Kummer; Francisco Cardoso; Antonio Lucio Teixeira; Natalia Pessoa Rocha
Journal:  J Clin Neurol       Date:  2018-09-06       Impact factor: 3.077

9.  Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.

Authors:  Amy W Amara; Kimberly H Wood; Allen Joop; Raima A Memon; Jennifer Pilkington; S Craig Tuggle; John Reams; Matthew J Barrett; David A Edwards; Arthur L Weltman; Christopher P Hurt; Gary Cutter; Marcas M Bamman
Journal:  Mov Disord       Date:  2020-02-24       Impact factor: 10.338

10.  Clinical Characteristics, Iron Metabolism and Neuroinflammation: New Insight into Excessive Daytime Sleepiness in Parkinson's Disease.

Authors:  Yang Hu; Peng Guo; Teng-Hong Lian; Li-Jun Zuo; Shu-Yang Yu; Li Liu; Zhao Jin; Qiu-Jin Yu; Rui-Dan Wang; Li-Xia Li; Ying-Shan Piao; Wei Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-21       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.